For the patients on trial, I hope they don't progress with the disease.
Just reading some old stuff. On Feb 28, 2013, ACL announced that 71 patients are in a trial sub-study (pharmacokinetic and cardiotoxicity). The additional 25 patients recruited were also for this sub-study.
"The optional pharmacokinetic and cardiotoxicity sub-study conducted along with the pivotal trial is intended to provide further confirmation of HA-Irinotecan's safety profile"
Well, I can assume they have an idea on 96 patients taking HA-I. Am I correct guys?
- Forums
- ASX - By Stock
- attendance at agm
For the patients on trial, I hope they don't progress with the...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online